Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
Current Opinion in Urology|August 2, 2008
Can we still afford bladder cancer?Arnulf Stenzl, Joerg Hennenlotter, David SchillingAsian Journal of Andrology|January 18, 2011
A self-reported long-term follow-up of patients operated with either shortening techniques or a TachoSil grafting procedureMarcus Horstmann, Matthias Kwol, Bastian Amend, et al.Cancer Biomarkers : Section a of Disease Markers|March 15, 2015
PCA3 and PSA gene activity correlates with the true tumor cell burden in prostate cancer lymph node metastasesIgor Tsaur, Joerg Hennenlotter, Elsie Oppermann, et al.Cancer Letters|November 10, 2011
Thymidine kinase and cancer monitoringStefan Aufderklamm, Tilman Todenhöfer, Georgios Gakis, et al.Journal of Cancer Research and Clinical Oncology|October 29, 2018
mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevanceSteffen Rausch, Daniel Schollenberger, Joerg Hennenlotter, et al.World Journal of Urology|November 30, 2010
XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinomaGeorgios Gakis, Joerg Hennenlotter, Marcus Scharpf, et al.BMC Urology|January 21, 2016
Assessment of a new point-of-care system for detection of prostate specific antigenSteffen Rausch, Joerg Hennenlotter, Josef Wiesenreiter, et al.Anticancer Research|December 11, 2013
Reliable housekeeping gene combination for quantitative PCR of lymph nodes in patients with prostate cancerIgor Tsaur, Markus Renninger, Joerg Hennenlotter, et al.Journal of Endourology|June 15, 2011
Interventional stress in renal stone treatmentStephan Kruck, Markus Sonnleithner, Joerg Hennenlotter, et al.Urologic Oncology|December 2, 2011
Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinomaTilman Todenhöfer, Joerg Hennenlotter, Veronika Tews, et al.Pageof 4